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This review touches on the historical links between epilepsy, seizures and the uterus and ovaries which have fascinated and
misled physicians since Greco-Roman times. It then examines present knowledge of ovarian function and its effect on epileptic
activity and vice versa before exploring the modern controversy about polycystic ovaries and the polycystic ovary syndrome,
epilepsy and anticonvulsant medication. Based on present evidence, women with epilepsy are more prone to develop polycystic
(polyfollicular) ovaries than other women due to the epilepsy itself. But women with epilepsy related polycystic (polyfollicular)
ovaries are vulnerable to the effects of sodium valproate (possibly particularly during adolescence) and may develop the
polycystic ovary syndrome: this is reversible if the valproate is withdrawn. Lamotrigine and carbamazepine seem to prevent
the development of the syndrome.
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INTRODUCTION
‘Into her womb convey sterility.
Dry up in her the organs of increase’
Shakespeare, King Lear.
The female organs of reproduction, initially the
uterus and later the ovary, have been long connected
in the (usually male) medical mind with seizures,
whether non-epileptic or the genuine article. There
was a Greco-Roman belief, said to be found in
the writings of Hippocrates and later expounded by
Galen, that seizures in women were caused by the
uterus moving from its proper place, rising from the
pelvis into the abdomen, sometimes into the thoracic
cavity and causing symptoms of ‘ smothering’ which
included convulsive behaviour. When these ancient
writings were ‘rediscovered’ from the 14th century
onwards, this gynaecentric idea became elaborated to
include both seizures themselves plus a whole host of
anxiety based symptoms eventually going under the
rubric of ‘hysteria’ (related to hystera, the Greek word
for the womb). The terms ‘suffocation of the mother’
or ‘fits of the mother’ (the mother being the uterus)
were in widespread use in the 16th and 17th centuries
with some attempt to separate these symptoms from
epilepsy itself. We still find some echoes of these
terms and ideas in our own day. We still use the term
‘globus hystericus’ to describe the anxiety symptom
of a lump in the throat and difficulty in swallowing,
although the term hysteria is now obsolete. Victorian
ladies, culturally addicted to swooning, were made
to inhale sal volate (ammonia) much as people with
epilepsy, from ancient times, were made to inhale
burning hartshorn. There was a longstanding belief
that similar disorders did not exist in men who, fairly
obviously, lack a uterus. Shakespeare was slightly
before his time using the term ‘hysterico passio’ in
a male context although, as has been demonstrated,
there were other reasons for his use of this term1.
The remedy for uterine perambulation was designed
to drive the errant organ back to its proper place.
This included getting the patient to inhale unpleasant
or noxious fumes to drive the womb away from the
chest and, sometimes, the placing of sweet smelling
substances into the vagina to encourage rapid return of
the uterus (it seems that this was more likely to be used
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if the physician felt that the seizures so treated were of
a non- epileptic nature). Such treatment was certainly
still in use in England in the early 17th century2.
The long held belief that the uterus was responsible
for neurological symptoms may, in part, have been
due to a mistranslation of the original Hippocratic
writings, which were actually a gynaecological text3.
In mediaeval times this rather absurd belief was
perpetuated by academic authoritarianism which
prevented rational discussion of the ancient’s ideas;
very much in the same way as the Galenic practice
of bleeding (which he seems to have developed from
noticing that natural menstruation in women seemed to
relieve certain symptoms) continued for hundreds of
years despite what must have been obvious evidence
that it was not only futile but dangerous (particularly
on the battlefield). Luckily for women the other
Greco-Roman medical belief that therapeutic sexual
intercourse cured these uterine-based neurological
problems seems to have died out quite early on.
Perhaps it was also lucky for women that the
structure of the ovary was not fully described (except
in animals) until the 16th century by Vesalius and his
pupils in Padua. The function of the ovary was not
fully recognized until the 18th and 19th centuries. In
the 19th century gynaecological surgeons discovered
the apparent importance of the ovary in the causation
of epilepsy in women. From the mid 19th century
onwards they began to remove ovaries to cure epilepsy
(this may have been triggered by the recognition of the
waxing and waning of seizure frequency during the
menstrual cycle). Indeed the view was expounded that
‘gynaecology represents the bridge between general
medicine and neuropathology’4. Battey’s operation
(female castration) became a very popular treatment
for epilepsy (and other neuropsychiatric symptoms) in
young women. It persisted in use into the early part of
the 20th century, despite a heavy mortality rate. (Male
castration for epilepsy was little practised, although
bromide treatment for epilepsy was introduced in
the belief that excessive sexuality and masturbation
caused epilepsy in men.)
Luckily Battey’s operation eventually disappeared
though controversy continues up to the present day
about whether or not menstrual cycle related epilepsy
exists5: the consensus view is that it does. Interest
in other possible gynaecological relationships with
epilepsy has also persisted. There is still a quaint
gynaecological belief that removing the ovaries will
‘cure’ premenstrual seizures, ignoring the fact that
menstrual cycling and epilepsy are initiated in the
brain and not in the pelvis. Ovariectomy in a
premenopausal woman, however, leads to an acute
menopause, which has to be treated with depot
hormone replacement therapy, which can lead to
significant seizure increase if the woman has epilepsy.
There is evidence (reviewed by Herzog 1997)6,
that women with epilepsy, whether or not they are
taking antiepileptic drugs, are more likely to have
anovulatory cycles, polycystic ovaries and possibly the
polycystic ovary syndrome (PCOS). This is attributed
to changes in gonadtropic hormone synthesis and
release in the mid brain caused by recurrent epileptic
discharges in the same area6.
Interest in the endocrine effects of seizure discharge
on ovarian function, lukewarm at best, rapidly
intensified following the publication in 1993 of a
paper by Isoja¨rvi and his colleagues7 which suggested
that the increased incidence of the PCOS in women
with epilepsy was due to sodium valproate. This
paper was followed by others8, 9 which confirmed
the original findings, suggested that valproate might
cause this syndrome by increasing insulin resistance
(with an associated rise in serum insulin levels):
insulin resistance is known to be associated with the
PCOS. It was suggested that removal of valproate
and substitution of lamotrigine caused the PCOS to
regress.
These papers, unfortunately, (even though they are
flawed as will be described later) became the pivot of
a controversy about the relative merits of valproate
and lamotrigine, the manufacturers of lamotrigine
wishing to show that for women their product was
superior since it appeared not to induce the PCOS:
the manufacturers of valproate obviously resisted this
idea. This lead to clinicians taking sides before they
had had a chance of reading the controversial papers
thoroughly or developing an understanding of the
possible causes of polycystic ovaries and the PCOS.
Unfortunately this area is a minefield as ideas about
polycystic ovaries and the PCOS are undergoing a
significant change. To understand something of the
possible relationship between epilepsy, its treatment
and the ovary it is necessary to have an understanding
of the structure and function of the ovary, and the
nature of both polycystic ovaries and the syndrome
itself.
The ovary: from indifferent gonad to egg and
endocrine factory
For a full review of the embryology, structure, function
and dysfunction of the ovary see the relevant chapters
in Speroff, Glass and Kase 199910. Initially, when
the ovary first develops as the gonadal ridge in early
embryonic life it is undifferentiated (the indifferent
gonad) and has the potential to be either testis or
ovary. By the sixth to ninth week of intrauterine life
differentiation into ovarian tissue begins. Germ cells
multiply into oocytes: there are six to seven million
by 16–20 weeks of embryonic life (this number falls
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to about two million at birth and perhaps 400 000 by
puberty). After puberty many oocytes will develop
into follicles part way toward ovulation: but only
400–500 will be ‘chosen’ for ovulation: the rest,
having advanced a little way in the process will
decline and disappear (‘atretic follicles’): for every
follicle that develops into ovulation, nearly 1000 will
become atretic. It takes about 85 days for a primordial
follicle to develop to ovulation. Maturity needs follicle
stimulating hormone (FSH) activity, but other factors
are involved: rupture of the follicle at the appropriate
time is dependant on a prostaglandin synthesis surge
within the follicle; the midcycle gonadotrophic surge
may also help this process, which, if prevented, leads
to a corpus luteum with a trapped oocyte.
Thus scanning of the ovary at a point in time
will reveal developing follicles, one or two pre-
ovulatory (Graafian) follicles, possibly a recently
ruptured follicle and atretic follicles. After release of
the egg, the corpus luteum develops: it persists if the
egg is fertilized, but if it is not the corpus luteum
degenerates into the corpus albicans and disappears:
menstruation occurs and the egg or its remains washed
out on the menstrual tide as the cycle begins again.
The process of selection of successful follicles and
the apoptosis of unsuccessful atretic follicles depends
on complex factors: follicles at a critical stage of
development respond to FSH stimulation with the
development of an oestrogen microenvironment which
promotes further development: but oestrogen release
inhibits FSH production: the decline in FSH release
inhibits further growth of the less mature follicles.
Apoptosis occurs when unsuccessful follicles begin to
secrete tumour necrosis factor (TNF) which inhibits
oestrogen production in the follicle mediated by FSH.
Increasing levels of TNF hasten the physiological
death of the follicle.
Corpus luteum development is initiated by the mid-
cycle release of luteinizing hormone (LH) with FSH.
This midcycle surge is responsible for inhibition of
oestrogen production at midcycle (with a subsequent
rise prior to menstruation) and increases progesterone
production in the ovary. LH increases testosterone
production in the ovary as well. Testosterone is
converted into oestrogen within the follicle: but too
much testosterone overwhelms this mechanism and
renders the follicle atretic. Insulin-like growth factor
(ILGF) is also important in modulating this process: a
rise in plasma insulin may, therefore, affect it.
The ovary is therefore not only a factory for the
production of eggs for fertilization, but a complex
endocrine organ as well: it has been said ‘the complex
events that yield an ovum for fertilization and ovarian
structures that provide hormonal support are the
products of essentially every regulating mechanism
in human biology10’. Changes in gonadotrophic
secretion can have profound effects on ovarian
homeostasis and hormone production: this is a two
way relationship. Hormone production in the ovary
is from the cells that line the follicles and from the
stroma itself, which is particularly the site of androgen
production: human and primate stroma has autonomic
nervous system innervation (not found in the rest of
the animal kingdom). The stroma is composed of
interstitial cells and connective tissue.
At puberty, and at the end of reproductive life,
many cycles are anovulatory: anovulatory cycles,
due to increased FSH stimulation, tend to release
more oestrogen and testosterone from the ovary and
are usually shorter. At menarche therefore ovarian
function may be more vulnerable to external factors
which alter the delicate homeostasis between midbrain
and ovarian hormone production.
Ovarian scanning
The conventional method of scanning the ovary is by
ultrasound, either through the abdomen (which can be
inaccurate, particularly in the obese) or transvaginally,
which is more accurate but more intrusive and
may still miss structures outside the cone of sound.
Ultrasound has the advantage that it can be frequently
repeated, so that changes in ovarian structure can
be closely monitored (and reveal that the ovary is
a dynamic and not a static structure). Experienced
operators can make mostly reliable judgments about
the nature of the content of ovarian cysts and can
estimate the volume of the ovary, its cysts or its stroma.
Full interpretation of a scan requires a great deal of
experience. Almost all the literature on the prevelance
of ovarian cysts is derived from ultrasound studies.
MRI scanning of the pelvis has also been used to
study the structure of the ovary and indeed may well
be more accurate11. It is more costly than ultrasound,
and this factor alone precludes it’s repetitive use so
that it only provides a snapshot of ovarian structure at
a moment in time. It is likely to be more widely used
in the future. Further experience of the method will
increase the accuracy of the prediction of the contents
of ovarian cysts. A normal MRI scan of the ovaries,
with the expected number and size of cysts is shown
in Fig. 1. MRI, because it is cross sectional and three
dimensional, can provide very accurate estimates of
size and volume both of the ovary and its cysts.
A scan of the ovary (either good quality ultrasound
or MRI) can reveal:
(1) a normal sized ovary, with the expected number
of cysts of normal size (i.e. pre-ovulatory,
ovulatory and atretic cysts;
(2) a normal sized ovary with more than the
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Fig. 1: Normal appearances of the ovary on MRI scanning.
expected number of cysts (but of normal size)—
usually assumed to be an increased number of
atretic cysts;
(3) or a normal sized ovary with larger than usual
cysts;
(4) or an ovary with stromal enlargement in
addition to an increased number (and/or size) of
cysts (Fig. 2). The meaning of these findings is
open to different interpretations.
The ‘cysts’ are of course, follicles. Referring to them
as cysts has lead to much confusion.
Polycystic ovaries and the PCOS
In 1937 Stein and Leventhal, two American gynae-
cologists, published a paper12 describing a group of
women who were hirsute, obese, had severe menstrual
irregularities and were infertile. At laparotomy they
were found to have enlarged ovaries with multiple
large cysts. Resection of wedges of their enlarged
ovaries returned menstruation to normal and restored
fertility, at least for a while. At this time, modern
endocrinology was in its infancy: later investigation
of this initially structural syndrome showed that
such women had high testosterone and luteinizing
hormone levels. The concept of the PCOS therefore
changed to encompass these endocrine findings
and was thought to be associated with obesity,
hirsutism and infertility. Later it was recognised that
women with this syndrome were at increased risk of
endometrial carcinoma (due to irregular menstruation)
and possibly of ovarian and breast carcinoma and of
the early development of diabetes and atherosclerotic
disease.
Developments in ultrasound scanning showed that
many women, even those of normal weight with nor-
mal menstruation and with no measurable endocrine
change and without enlarged ovaries, had more cysts
in their ovaries than was usual: these have also
been confusingly called ‘polycystic’. The meaning
of this finding is controversial. It is so common
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Fig. 2: Polycystic ovaries: note increase in ovarian volume. MRI scan.
that many authorities do not regard it as abnormal
and rightly prefer the term ‘polyfollicular ovary’ to
‘polycystic ovary’13. If young women, with entirely
normal menstrual cycles, are examined by ultrasound
the incidence of polyfollicular ovaries is about 8–
10%14.
There is also a dichotomy between European and
United States practice. The diagnosis of the PCOS
in the States is made without recourse to ultrasound
scanning: (indeed some authorities warn vigorously
against this practice10).
Most authorities nowadays draw a distinction be-
tween women who merely have polyfollicular ovaries
but no hormonal changes and those women that have
polyfollicular ovaries (often with somewhat enlarged
stroma) who do have the hormonal changes consistent
with the so-called PCOS (raised testosterone &/or
luteinizing hormone levels or a reversed FSH/LH
ratio). Such women are often (but not invariably)
overweight, and hirsute with menstrual irregularity:
but some women of normal weight who are not
hirsute can also have it. In Europe the ovary is
considered polycystic if it contains, on ultrasound
examination, at least 10 cysts between 2 and 8
mm in diameter, particularly if associated with an
increase in ovarian stroma15. The prevalence of the
PCOS has been estimated as between 5% and 26%
of the female population in the United Kingdom,
depending on the definition used16. The aetiology of
the PCOS is controversial17. The primary dysfunction
at various times has been suggested to be in the
hypothalamic/pituitary axis, in the adrenal or the ovary
or that all the clinical manifestations are due to
hyperinsulinaemia.
There is increasing evidence for a major genetic
component for polycystic ovaries and the PCOS.
Strong familial clustering has been shown with a
high prevalence amongst siblings18, 19. Although an
autosomal dominant mode of inheritance has been
suggested because of the heterogenicity of the PCOS
it is most likely to be due to a complex trait in
which a small number of genes interact with external
environmental factors and other genetic factors, thus
affecting the expression of the syndrome19.
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Genetic studies have shown possible abnormalities
in the regulation of the expression of the insulin
gene and abnormalities in the genes involved in
steroidogenesis16, 19. The possible involvement of the
insulin gene adds to the importance of the role of
hyperinsulinaemia, secondary to insulin resistance, in
the PCOS, which is now thought by many to be the
key to the pathogenesis of the syndrome16. This view
is supported by a study showing that 82% of women
with Type II diabetes (a condition also known to
be associated with insulin resistance) had polycystic
ovaries on ultrasound and 52% had symptoms of
the PCOS20. Insulin resistance is most evident in
overweight patients18 although insulin concentration
has still been shown to be higher in both lean
and obese patients with the PCOS than in control
populations20.
Insulin affects the ovary, in combination with an
elevated luteinizing hormone concentration, by caus-
ing thecal cell hyperplasia, increased androgen levels,
arrested follicular development and, thus, anovulation
with menstrual disturbance19. This disturbance of
normal ovarian function results in multiple small cysts
in the ovaries, which mostly contain potentially viable
oocytes within dysfunctional follicles17. Insulin also
acts on the liver to inhibit production of both sex
hormone binding globulin (leading to increased free
testosterone) and insulin-like growth factor 1 binding
protein (causing increased free insulin-like growth
factor 1 and enhancing further ovarian androgen
production)19. As well as hyperinsulinaemia, other
factors may affect the expression of the PCOS. Weight
gain worsens symptoms: feedback from the polycystic
ovary to the pituitary and the hypothalamus seems
to play a part in the syndrome as it is disturbed by
abnormalities in the secretion of ovarian steroidal and
non-steroidal hormones17.
The pathogenesis of the PCOS is probably multifac-
torial and not purely due to hyperinsulinaemia. Indeed
Speroff, Glass and Kase, 199910 make powerful argu-
ments that ‘the characteristic polycystic ovary emerges
when a state of anovulation persists for any length of
time. . . because there are many causes of anovulation,
there are many causes of polycystic ovaries. A similar
clinical picture and ovarian condition can reflect any
of the dysfunctional states discussed above. In other
words the polycystic ovary is the result of a functional
derangement, not a specific central or local defect’.
There is no doubt, however, that a raised insulin
level, often due to insulin resistance, does seem to
be an important aetiological factor in some of the
characteristics of the PCOS.
Although most authorities do make a clear distinc-
tion between merely possessing poly-follicular ovaries
and having the PCOS it is currently uncertain whether
women who have polyfollicular ovaries, but no present
evidence of the hormonal changes that go with the
PCOS, will eventually develop the syndrome: does
possession of polyfollicular ovaries mark an early
stage of the full syndrome, a vulnerability to it, or
are they, as some think,13 unconnected? What is
clear, however, is that what was initially seen as a
structural syndrome (indeed in the early days the
cysts were surgically treated or wedges of ovarian
tissue were removed12—which resulted in temporary
improvement due to excision of androgen secreting
tissue of the ovary), is now seen as an hormonal
and metabolic syndrome19, with the structural changes
now considered to be secondary.
The time of first expression of the PCOS may also
be important in discussing its pathogenesis. Polyfol-
licular ovaries can be detected in early childhood,
before puberty, and the onset of the syndrome may
occur in late childhood. Since many of the metabolic
and endocrine features of the disorder are similar
to those that naturally occur during puberty (for
example insulin resistance, increased testosterone and
luteinizing hormone levels and anovulatory cycles) it
may be that females genetically predisposed to the
PCOS fail to resume normal insulin sensitivity and
thus continue to express features usually confined to
puberty itself19.
This may be important to the putative relationship
between sodium valproate and the PCOS.
The PCOS and epilepsy
There is some evidence to suggest that menstrual
disorders, polyfollicular ovaries and the PCOS (and,
therefore, relative infertility), may be more common in
women with epilepsy than in the general population6.
It has to be said that the evidence for this is somewhat
shaky, based on small populations and probably
conflated results, and some population studies of
women suggest that these abnormalities may be just
as common in women who do not have epilepsy.
Further large-scale studies in unselected populations
of women with epilepsy are needed to resolve whether
this relationship exists or not.
If women with epilepsy do have an increased
prevalence of menstrual disorders and the PCOS, it
may be that the epilepsy itself is implicated. Women
with epilepsy, even those not on active treatment
have been shown to have an altered LH pulse
frequency21, 22. It is possible that epilepsy interferes
with the gonadotrophic releasing pulse generator
(i.e. it increases gondadotrophin releasing hormone
pulse frequency) which affects ovarian function by
inhibiting ovulation producing poly-follicular ovaries
and later the PCOS21, 22. It has been suggested that
this might be more common in women with partial
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seizures as opposed to primary generalised epilepsy21,
but an increased occurrence of the PCOS has also
been reported in women with primary generalised
epilepsy22.
An alternative theory to explain the probable
increased frequency of menstrual disorders and the
PCOS in women with epilepsy is that a primitive
neuro-transmitter dysfunction is present which gives
rise to both the seizure disorder and abnormal
gonadotrophic releasing hormone secretion, in turn
producing polyfollicular ovaries and the PCOS22.
There is evidence that anovulatory cycles may be
associated with more frequent seizures. If a woman
has the PCOS her anovulatory cycles expose the
brain to higher levels of oestrogen but without cyclic
progesterone release, producing a potential worsening
of seizure control in women with both the PCOS and
epilepsy (progesterone is potentially anticonvulsant,
oestrogen proconvulsant)23.
The issue is still not resolved whether it is a
particular form of epilepsy, or a separate genetic
predisposition for polycystic ovaries and the PCOS
or a combination of both that produces the irregular
gonadotrophin releasing hormone pulsatile secretion
(which leads to irregular luteinizing hormone secre-
tion) and thus the reproductive endocrine disorders in
women with epilepsy6, 22. It may be that luteinizing
hormone hyperpulsive activity, which is a condition
associated with epilepsy, makes women with epilepsy,
possibly already genetically predisposed to the PCOS,
more likely to develop symptoms of it than if they
had not suffered with epilepsy. It could also be that
women with polyfollicular ovaries or the PCOS are
more prone to epilepsy itself (as such women are to
diabetes) and there is a shared genetic predisposition
to both. The science of the molecular genetics of
epilepsy is making rapid strides and may possibly
provide an answer to this question in due course.
Polycystic ovaries, PCOS, sodium valproate and
other anticonvulsants
Although women with epilepsy may already have
a higher instance of the PCOS and polyfollicular
ovaries, it has been suggested that treatment with
sodium valproate increases this risk further7–9. This is
a controversial view: others have produced evidence to
suggest that sodium valproate is not significantly asso-
ciated with polyfollicular ovaries or the PCOS24, 25.
Isoja¨rvi and his colleagues7–9 showed that, in the
population of women that they studied, polycystic
ovaries or elevated testosterone levels (hyperandro-
genism) were found in the majority (64%) of women
receiving valproate as therapy for their epilepsy, but
in women receiving medication other than valproate,
they found that the frequency of polycystic ovaries
and of hyperandrogenism did not differ from that of
normal women.
These studies have been strongly criticized26. It has
been suggested that Isoja¨rvi and colleagues muddled
the definition of polycystic ovaries, so that women
who only had polyfollicular ovaries were joined with
those that had raised androgen levels with or without
polyfollicular ovaries. It is difficult to determine
from the publications if some women from the first
series7 were included (or not) in the second series8.
The decline in the number of cysts reported after
the substitution of lamotrigine for valproate is not
statistically significant and the population studied was
a very selected one9. The women in the study may
have been unintentionally selected for their obesity
since their original body mass index (before treatment
with valproate) is not stated: were they always obese
or did they gain weight on valproate? Was there any
evidence of similar weight gain in the control group?
It is also not clear whether the hormone measurements
were taken at the right point in the menstrual cycle,
and at the same time of day (there are both cyclical
and diurnal changes in hormone levels).
These criticisms are important, because Isoja¨rvi
and his colleagues ascribe the increased incidence of
polycystic ovaries and the PCOS in women taking
valproate to the weight gain that may go with taking
valproate8 (though not all the patients in their series
with the PCOS were overweight). Valproate increases
insulin levels, possibly due to its effect on insulin
resistance8: which may lead to the hormonal and
structural ovarian changes characteristic of the PCOS.
These studies, although widely quoted, are seriously
flawed. But they do raise important questions, since
the PCOS has important consequences: relative
infertility, possible later diabetes and malignancy. If
an anticonvulsant is ‘causing’ such a syndrome it
would be serious. How might this association be better
proven (or disproved)?
There are two possible solutions. The first would
be to study women at the start of their epilepsy,
before and after they start antiepileptic treatment in
monotherapy, and follow them up monitoring both
ovarian structure and hormonal profiles. Such a study
is underway in the UK26 but may have recruitment
difficulties: ovarian structure is being assessed by
abdominal ultrasound which may not be particularly
reliable. But it is a study worth supporting.
The second solution is to examine groups of
women who have only ever taken one antiepileptic
drug in monotherapy (and who have the same type
of epilepsy) and examine their body mass index,
ovarian structure and hormonal profile. Such a study
is being carried out in our department (using ovarian
MRI scanning). It is still ongoing but early results27
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suggest in a group of young women taking either
valproate, lamotrigine or carbamazepine in exclusive
monotherapy for primary generalised epilepsy that:
(A) There is no difference in body mass index
between the three groups.
(B) The prevalence of polyfollicular/polycystic
ovaries is high (59%).
(C) The prevalence of polyfollicular/polycystic
ovaries is the same in the three groups.
(D) In the women with polyfollicular/polycystic
ovaries it is only in the group taking valproate
that raised testosterone/ and or luteinizing
hormone levels are found.
(E) Substitution of lamotrigine for valproate leads
to an immediate drop in testosterone and/or
luteinizing hormone level, before the valproate
is withdrawn.
(F) After valproate withdrawal there is some evi-
dence of reduction in ovarian volume and cyst
size.
(G) The ‘valproate effect’ may be age specific, more
likely to occur in those women taking valproate
at around puberty.
These results are interesting and, if confirmed in
a larger series (using a control population) suggest
that Isoja¨rvi and his colleagues were partly right,
but also partly wrong. Our study so far suggests
that valproate does not cause polyfollicular/polycystic
ovaries in women with epilepsy: they are already there
and are presumably due to the epilepsy. Valproate,
unlike the other two antiepileptic drugs, may push
women (already pre-disposed by having polyfollicular
ovaries) down the metabolic pathway towards the
PCOS (possibly by raising insulin resistance) but
this effect is reversible. The other two drugs seem
protective against this effect, carbamazepine possibly
by its enzyme inducing effect reducing levels of
unbound testosterone: the mechanism of lamotrigine
protection, since the drug is not enzyme inducing, is
unknown.
These findings have changed our policy toward
female adolescents coming into our care: if they
are on valproate monotherapy we investigate ovarian
structure and function. If they have polyfollicular
ovaries (or have evidence of the PCOS) we withdraw
the valproate and substitute another appropriate drug:
if ovaries and hormones are normal and the patient
is seizure free they can stay on the valproate for a
while (but it is withdrawn later, before they wish to
conceive).
In evaluating conflicting papers on the effect of
valproate on ovarian structure and function it is
important to ask whether the patients are on valproate
monotherapy and always have been or not and at
what age they started to take valproate. Women taking
valproate plus an enzyme inducing drug may not
show the valproate ovary effect, and nor, probably,
will women starting valproate later in life: we have
shown27 that women taking a mixture of lamotrigine
and valproate do not show this effect. It is probably
more likely to be seen in girls taking valproate before
or during puberty whose ovarian function may be
already vulnerable.
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